Nektar Therapeutics Shareholders' Equity
Nektar Therapeutics (NKTR) had Shareholders' Equity of $903.12 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent $903.12M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $576.22M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $89.83M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $85.09M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $903.12M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $576.22M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $89.83M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $85.09M 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$24.21M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $13.74M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $60.74M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $48.88M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $79.69M 10-Q · filed 2025-11-07 |
| 2024-03-31 | $126.70M 10-Q · filed 2025-11-07 |
| 2023-12-31 | $130.99M 10-K · filed 2026-03-13 |
| 2023-09-30 | $159.37M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $196.96M 10-Q · filed 2024-11-08 |
| 2023-03-31 | $240.87M 10-Q · filed 2024-11-08 |
| 2022-12-31 | $366.64M 10-K · filed 2025-03-14 |
| 2022-09-30 | $412.22M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $458.73M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $607.89M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $679.51M 10-K · filed 2024-03-05 |
| 2021-09-30 | $801.54M 10-Q · filed 2022-11-04 |
| 2021-06-30 | $904.98M 10-Q · filed 2022-11-04 |
| 2021-03-31 | $994.51M 10-Q · filed 2022-11-04 |
| 2020-12-31 | $1.08B 10-K · filed 2024-03-05 |
| 2020-09-30 | $1.17B 10-Q · filed 2021-11-05 |
| 2020-06-30 | $1.26B 10-Q · filed 2021-11-05 |
| 2020-03-31 | $1.30B 10-Q · filed 2021-11-05 |
| 2019-12-31 | $1.41B 10-K · filed 2023-02-28 |
| 2019-09-30 | $1.49B 10-Q · filed 2020-11-06 |
| 2019-06-30 | $1.56B 10-Q · filed 2020-11-06 |
| 2019-03-31 | $1.63B 10-Q · filed 2020-11-06 |
| 2018-12-31 | $1.72B 10-K · filed 2022-03-01 |
| 2018-09-30 | $1.79B 10-Q · filed 2019-11-07 |
| 2018-06-30 | $1.86B 10-Q · filed 2019-11-07 |
| 2018-03-31 | $58.28M 10-Q · filed 2019-11-07 |
| 2017-12-31 | $87.83M 10-K · filed 2021-02-26 |
| 2017-09-30 | $84.16M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $3.39M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $44.75M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $88.13M 10-K · filed 2020-02-28 |
| 2016-09-30 | -$67.85M 10-Q · filed 2016-11-04 |
| 2016-06-30 | -$39.25M 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$275.00K 10-Q · filed 2016-05-04 |
| 2015-12-31 | $6.43M 10-K · filed 2019-03-01 |
| 2015-09-30 | $39.05M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $35.10M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $77.31M 10-Q · filed 2015-05-01 |
| 2014-12-31 | $36.33M 10-K · filed 2018-03-01 |
| 2014-09-30 | $47.22M 10-Q · filed 2014-11-07 |
| 2014-06-30 | -$35.36M 10-Q · filed 2014-08-01 |
| 2014-03-31 | -$9.81M 10-Q · filed 2014-05-08 |
| 2013-12-31 | -$89.90M 10-K · filed 2017-03-01 |
| 2013-09-30 | -$50.25M 10-Q · filed 2013-11-07 |
| 2013-06-30 | -$40.55M 10-Q · filed 2013-08-09 |
| 2013-03-31 | -$2.62M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $47.02M 10-K · filed 2016-02-29 |
| 2012-09-30 | $95.33M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $132.28M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $162.49M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $197.81M 10-K · filed 2015-02-26 |
| 2011-09-30 | $230.80M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $251.28M 10-Q · filed 2011-08-05 |
| 2011-03-31 | $281.24M 10-Q · filed 2011-04-29 |
| 2010-12-31 | $90.66M 10-K · filed 2014-02-27 |
| 2009-12-31 | $102.37M 10-K · filed 2013-03-01 |
| 2008-12-31 | $190.15M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |